Stage II, III or IV disease as defined by the Ann Arbor Staging System
Clinical stage II (T3-4, N-) or stage III (any T, N+) based on magnetic resonance imaging (MRI)
RMS types included under embryonal rhabdomyosarcoma (ERMS) include those classified in the 1995 International Classification of Rhabdomyosarcoma (ICR) as ERMS (classic, spindle cell, and botryoid variants), which are reclassified in the 2013 World Health Organization (WHO) classification as ERMS (classic, dense and botryoid variants) and spindle cell/sclerosing RMS (encompassing the historical spindle cell ERMS variant and the newly recognized sclerosing RMS variant); classification of alveolar rhabdomyosarcoma (ARMS) in the 2013 WHO classification is the same as in the ICR and includes classic and solid variants\r\n* ERMS\r\n** Stage 1, group III (non-orbit)\r\n** Stage 3, group I/II\r\n** Stage 2/3, group III\r\n** Stage 4, group IV, < 10 years old\r\n* ARMS:\r\n** Stages 1-3, groups I-III
Patients must have stage II, III, or IV disease
Stage III-IV SCCHN and select stage II participants (T2N0 oral cavity cancer with > 5 mm depth invasion)
Ann Arbor stage II-IV disease (Stage I primary mediastinal B-cell lymphoma will also be eligible)
Histologically confirmed CD30-positive, CD20-positive untreated primary mediastinal B-cell lymphoma (any Ann Arbor stage), diffuse large B-cell lymphoma (Ann Arbor stage III or IV), or grey zone lymphoma (any Ann Arbor stage); patients with heterogeneous, weak or equivocal CD30 staining will also be included (no specific cut off percentage for CD30 stain is required)
Stages II, III, or IV (Ann Arbor Staging)
CLL (Part 1): Rai Stage III or IV disease, or stage 0-II disease that meets National Cancer Institute Working Group (NCIWG) criteria for active disease requiring therapy that may include either of the following disease-related symptoms:
Stage I, II, III, or IV disease; NOTE: stage I disease are eligible only if the disease is not amenable to external beam radiation therapy
Prior endoscopic mucosal resection (EMR) with a diagnosis of stage II or III esophageal cancer is eligible, irrespective of margin status
Ann Arbor stage II-IV
Eligible tumors must meet one of the following criteria: Stage II or III, or T4, any N, M0, including clinical or pathologic inflammatory cancer or Regional Stage IV, where supraclavicular lymph nodes are the only sites metastasis
Inoperable per local Investigator (Masaoka stage III or IV)
Female subjects with CA125-associated, advanced ovarian cancer (FIGO Stage III/IV) previously treated and now presenting with recurrent or persistent disease.
Cohort 1: Phase II: patient must have HER2+ (regardless of hormonal receptor status) stage III IBC
AJCC stage III/IV differentiated thyroid cancer
Patients with histologically-confirmed Low Tumor Burden Follicular Lymphoma, without B symptoms, Ann Arbor stage II to IVA NHL (CD20+ FL of Grades 1, 2, or 3a)
Radiographically confirmed endometrial adenocarcinoma of stages III-IV requiring adjuvant therapy; if stage III disease is suspected, there should be multiple pelvic and/and or lymph nodes involved
Have TNM clinical stage III, IVA, or IVB disease
All patients with Surgical Stage III or IVA endometrial carcinoma per FIGO 2009 staging criteria, including clear cell and serous papillary and undifferentiated carcinomas.
Ann Arbor stage I - stage IV DLBCL at the time of relapsed/refractory disease to be eligible
Disease must be stage III or IV
Prior endoscopic mucosal resection (EMR) with a diagnosis of stage II-III esophageal cancer is eligible
Ann Arbor stage I or II disease
Ann Arbor Stage II, III or IV
Stage I-III (according to ENSAT classification 2008; see Appendix 2)
Visceral aGVHD defined as: at least stage III/IV acute liver or stage II/III gastrointestinal (GI) GVHD by clinical criteria and/or GI and/or liver biopsy confirmation showing no alternative explanation for symptoms of GVHD
Patients must have Durie-Salmon stage II or III disease
Clinical stage III or IV
Patients with metastatic disease (only stage III or IVA-B patients permitted)
At least one adverse prognostic factor: \r\n* Initial relapse =< 12 months after primary chemotherapy\r\n* Staged as Ann Arbor classification initial stage III or IV disease\r\n* Chemotherapy resistant disease\r\n* Failure to achieve a complete response (CR) with cytoreductive chemotherapy or persistent positive fludeoxyglucose F 18 (18FDG)-positron emission tomography (PET) imaging
All Stage IV patients are eligible, irrespective of residual disease, after primary or interval debulking. Stage III patients are required to have visible residual disease after primary surgery. Patients with inoperable Stage III and IV disease are eligible
Patients must have non-bulky stage I or II disease by Ann Arbor classification\r\n* This staging excludes fludeoxyglucose F 18 (FDG)-PET evaluation\r\n* Patients who have stage I or II non-bulky disease based on diagnostic CT scan, but are upstaged to stage III or IV based on FDG-PET evaluation, are also eligible\r\n* Stage and bulk are assigned using measurements obtained prior to biopsy
ISS Stage III; or
ISS stage III; or
Stages II bulky disease (defined as mass size of more than 10 cm), stage III, or IV (Ann Arbor staging); patients with stage I and stage II non-bulky disease are excluded from this study
Clinical Masaoka stage II (> 5 cm), III, or IVA, including suspected invasion of mediastinum, pericardium, lung, great vessels or chest wall, and/or pleural metastases
Ann Arbor stage II to IV.
Patients with selected Stage III or IV disease (T2 N2-3 M0, T3-4 any N M0, T1 N2b, N2c or N3p16 negative oropharynx cancer or T1-2 any N hypopharynx cancer) including no distant metastases.
Stage II, III, or IV disease
Patients must have histologically confirmed advanced (FIGO Stage III or IV), persistent, or recurrent endometrial carcinoma, which is not likely to be curable by surgery or radiotherapy. Histologic documentation of the recurrence is not required.
Previously untreated stage III/IV advanced or metastatic MEL (Part 1C only)
Residual Cancer Burden (RBC) classification II or III6
Stage III A or B disease with minimum diagnostic evaluation within 6 weeks to include:
Ann Arbor stage 3 or 4 or stage 2 with bulky disease
Female patients must have high risk resected stage I or 2 disease (papillary serous, clear cell, carcinosarcoma histology or grade 3), advanced stage (III or IV, all histologies) or recurrent endometrial cancer (all histologies); patients do not need measurable disease and can enroll following surgery
Stage II, III, or IV disease
Stage III/IV disease by Ann Arbor Staging
Subjects must have histologically-confirmed diagnosis of IDH1 gene-mutated cholangiocarcinoma Stage II, III, or IV (intra-hepatic, extra-hepatic and perihilar) that is not eligible for curative resection, transplantation, or ablative therapies. Tumors of mixed histology are not allowed.
Residual Cancer Burden (RBC) classification II or III6
FIGO stage IA1, IB2, II, III or IV disease
Stage III/IV disease (stage II is also eligible if disease is not encompassible within a single radiation field)
Ann Arbor stage IIB, IIIB, IVA, or IVB
Stage II (not candidates for local x-ray therapy), III, or IV disease by the Ann Arbor Classification
Stage IB, II-A, II-B, III and IV
Histologically or cytologically proven B-cell malignancies; either Burkitt leukemia or B-AL (= Burkitt leukemia = L3-AL), or diffuse large B-cell NHL, or aggressive mature B-cell NHL non otherwise specified or specifiable (phase III)\r\n* Stage III with elevated LDH level (B-high) (LDH > twice the institutional upper limit of the adult normal values [> Nx2]), any stage IV, or B-AL (phase III)
Extent of disease: stage I - IV; patients with nodular histology mantle cell lymphoma must have Ann Arbor stage III or IV disease to be eligible\r\n* Patients with mantle zone type histology will not be eligible\r\n* Patients with other mantle cell histologies are eligible regardless of stage
Stages II-IV of the above cancer
Intra-abdominal desmoid disease, stage III or IV
Stage II, III, and IV disease by Ann Arbor classification
Stage III or IV disease, or Stage II bulky disease (defined as tumor diameter greater than or equal to [>/=] 7 centimeters [cm])
Ann Arbor Stage I disease
Histologically confirmed diagnosis of follicular lymphoma CD20+ (Grade 1, 2 or 3a) Ann Arbor Stage II, III or IV disease.
Patients with Rai stage III-IV - OR - Patients with Rai stage 0-II
FIGO stage II-IV;
Stage II, III or IV cardiac failure
Disease may be stage I, II, III or IVA (as long as it is deemed resectable by the surgical team)
Diagnosed with radiologically and biopsy or cytology confirmed inoperable perihilar cholangiocarcinoma Bismuth Tumor Stage III/IV
Patient must have measurable stage IV disease (includes M1a, M1b stages or recurrent disease) (according to the 7th edition of the TNM classification system); however, patients with T4NX disease (stage III B) with nodule(s) in ipsilateral lung lobe are not eligible, because such patients were not included in historical controls
Stage III or IV disease at any time in the past (Ann Arbor Staging System for Non-Hodgkinâ€™s Lymphomas)
Ann Arbor Stage II, III, or IV
Stage II, III or IV disease
Stage II disease with bulky disease (? 7cm lesion), Stage III, or Stage IV disease
Histologically or cytologically confirmed squamous cell carcinoma, previously untreated stage II, III, or IVA HNC; patients with clinical stage III or IVA disease must undergo computed tomography (CT) or magnetic resonance imaging (MRI) to rule out the presence of distant metastases
Advanced (FIGO stage III or IV), recurrent or metastatic disease.
Part III:
Stage II, III or IV (Ann Arbor Staging)
Patients must have suspected International Federation of Gynecology and Obstetrics (FIGO) stage III or IV disease
Ann Arbor stage I disease.
Inoperable or metastatic extra cranial stage III or IV disease
Stage I-III
Ann Arbor stage III or IV disease at diagnosis or at relapse/refractory disease confirmation
Ann Arbor stage III or IV disease (Cohort A only)
Localized endometrial cancer (stage I and II); no evidence of stage III or IV disease
Mallampati I-III
Diagnosis of adenocarcinoma colorectal cancer (stage I, II, III, IV)
Stage I-III
Staging to rule out metastatic disease is recommended for subjects with clinical stage III disease
Histologic or cytologic confirmation of head & neck cancer (stage I-IV) or non-small cell lung cancer (stage II & III)
Stage I, II, and III prostate cancer
Stage II, III, or IV NSCLC for whom radiation therapy of 60 Gy and concurrent weekly paclitaxel/carboplatin is recommended
Participants undergoing definitive surgery at diagnosis must have pathologic stage II or III disease
Participants undergoing preoperative systemic therapy must have clinical stage II or III disease at presentation (clinical stage I disease is excluded)
Prior systemic therapy, radiotherapy, or investigational agent in participants undergoing surgery for stage I, II, or III colon cancer
Patients undergoing unilateral SLNDs either levels I-III, I-IV, II-III, or II-IV for oral cavity, oropharynx (if the resection does not connect to the neck), thyroid, salivary gland, parotid, and skin carcinoma
A treatment plan involving levels I-III, I-IV, II-III, or II-IV, as recommended by National Comprehensive Cancer Network (NCCN) guidelines
stage II-III, planned to be treated with radical surgery
